Advertisement

Topics

Ligand Receives $2 Million from WuXi Biologics for Licensing anti-PD-1 Antibody Using OmniAb Technology

09:37 EDT 18 Aug 2017 | Speciality Pharma Journal

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories. Ligand is also entitled to future milestones and royalties …

Original Article: Ligand Receives $2 Million from WuXi Biologics for Licensing anti-PD-1 Antibody Using OmniAb Technology

NEXT ARTICLE

More From BioPortfolio on "Ligand Receives $2 Million from WuXi Biologics for Licensing anti-PD-1 Antibody Using OmniAb Technology"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...